6-K 1 v377512_6k.htm 6-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934

 

For the month of May 2014

 

Commission File Number: 000-28508

 

Flamel Technologies, S.A.

(Translation of registrant’s name into English)

 

Parc Club du Moulin à Vent
33 avenue du Dr. Georges Levy
69693 Vénissieux Cedex France
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

Indicate by check mark whether registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes o No x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-____________

 

In April 2014, Flamel Technologies issued the press releases attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

 
 

 

EXHIBIT LIST

 

Exhibit

Number

  Description
99.1   Press release announcing Receipt of Complete Response Letter From FDA Citing Issues at the Facility of the Supplier of the Active Ingredient

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated:  May 6, 2014 Flamel Technologies, S.A.

 

  By: /s/ Michael S. Anderson
    Name:  Michael S. Anderson
    Title:  Chief Executive Officer

 

 
 

 

EXHIBIT INDEX

 

Exhibit

Number

  Description
99.1   Press release announcing Receipt of Complete Response Letter From FDA Citing Issues at the Facility of the Supplier of the Active Ingredient